Semaglutide and Muscle Loss: What the Research Says and How to Fight Back

Here is a number that should give every man on semaglutide pause: up to 45% of the weight lost during GLP-1 receptor agonist therapy can come from skeletal muscle, not fat. That figure comes from and it reframes the entire conversation around these blockbuster drugs. Losing weight is the goal. Losing the muscle that drives your metabolism, protects your joints, and keeps you functional into old age is very much not the goal — and yet it’s happening to men every day who assume the number going down on the scale means everything is going in the right direction.

Semaglutide and its class of incretin-based medications have genuinely earned their reputation. Clinical trials show mean weight loss of 15–25%, reductions in major cardiovascular events, and a 72% decrease in type 2 diabetes incidence. That is not marketing language — those are landmark outcomes. But a growing body of research is pointing to a serious blind spot: the composition of that weight loss matters enormously, and right now, too many men are trading muscle for a lower number on the scale.

A 2024 analysis in Metabolism: Clinical and Experimental by Stefanakis, Kokkorakis, Mantzoros, and colleagues noted that over 25% of total weight lost from both bariatric surgery and pharmacotherapy typically comes from fat-free mass, including skeletal muscle. The authors flagged this as a pathway to sarcopenic obesity — a particularly dangerous condition where a person is simultaneously carrying excess fat and critically low muscle mass. In older men especially, this combination accelerates metabolic decline, increases fracture risk, and erodes the very functional capacity that makes life worth living. Understanding why this happens — and what you can do about it — is no longer optional if you are on these medications.

Why Semaglutide Targets Muscle in the First Place

The mechanism behind GLP-1-induced muscle loss is not a single switch being flipped — it is several things happening simultaneously. A 2026 review in the European Heart Journal by Khan, Dawood, Handelsman, and colleagues identified three primary drivers: caloric restriction, anabolic resistance, and hormonal shifts. When semaglutide suppresses appetite and dramatically reduces caloric intake, the body enters a state of significant negative energy balance. Without adequate protein and mechanical stimulus from exercise, the body begins breaking down muscle tissue for fuel — a physiologically logical but deeply counterproductive response for a man trying to preserve his strength and metabolic health.

The JCI Insight study added another layer to this picture. In preclinical models, semaglutide monotherapy suppressed mitochondrial gene expression in skeletal muscle while simultaneously elevating genes associated with muscle atrophy. In plain terms, the drug was impairing the energy-generating machinery inside muscle cells at the same time it was activating the cellular programs that break those cells down. This is why the muscle loss seen with GLP-1 therapy is not simply a byproduct of eating less — it has a distinct molecular fingerprint that requires targeted intervention.

There is also the myostatin-activin-follistatin axis to consider. Stefanakis and colleagues described how activins and myostatin — proteins that promote muscle degradation — become increasingly influential during states of negative energy balance. Follistatin, which normally counteracts these signals, is insufficient to keep pace during rapid pharmacologic weight loss. The result is a biochemical environment that tilts toward catabolism. This pathway is now the target of several emerging pharmaceutical agents, but the strategies available to men today are already effective when applied consistently.

The Evidence-Based Playbook for Preserving Muscle on Semaglutide

Resistance training is the single most powerful tool available. This is not a gym-bro opinion — it is the consensus position of multiple research groups and clinical guideline bodies. The European Heart Journal review is explicit: resistance training is the currently recommended strategy for preserving skeletal muscle and functional capacity during pharmacologic weight loss. The mechanical stress of loading muscle tissue creates an anabolic signal that directly counters the catabolic environment induced by caloric restriction and GLP-1 therapy. For practical purposes, this means a structured program hitting all major muscle groups two to four times per week, with progressive overload built in over time. Men who are new to lifting should not wait until they are more comfortable — the time to start is now, alongside the medication, not after.

Protein intake is the second non-negotiable. A 2025 consensus report in Obesity Pillars from a global working group convened at the International Symposium on Diabetes and Nutrition set a clear threshold: protein intake above 1.2 grams per kilogram of body weight per day, distributed evenly across meals. This is a higher target than most men naturally hit, and it becomes harder to reach on semaglutide because the drug reduces appetite and overall food volume. The implication is that protein has to become a deliberate priority at every meal — not an afterthought. Greek yogurt, eggs, lean meats, cottage cheese, and quality protein supplements are practical tools for hitting that ceiling when appetite is suppressed. Spreading intake across three to four meals rather than concentrating it at dinner also improves muscle protein synthesis, based on the distribution evidence cited in that same consensus document.

On the supplement front, one of the most intriguing findings in recent literature involves ketone esters. The JCI Insight study found that co-administering a beta-hydroxybutyrate-generating ketone ester with semaglutide preserved skeletal muscle mass and function in obese, glucose-intolerant mice without compromising fat loss. The mechanism appears to involve the restoration of mitochondrial gene expression and the suppression of atrophy-related genes — essentially reversing the molecular damage that semaglutide alone was causing in muscle tissue. The authors were careful to note these are preclinical findings requiring clinical validation, but the mechanistic logic is compelling and the safety profile of ketone esters is well-established. For men already interested in optimizing their approach, this is a legitimate area to watch and, in consultation with a physician, potentially explore.

Looking further ahead, pharmaceutical science is moving toward combination therapies that address this problem at its root. Stefanakis and colleagues highlighted agents like Bimagrumab and Trevogrumab, which inhibit activin and myostatin signaling, as promising compounds that could be paired with GLP-1 therapies to simultaneously drive fat loss and preserve or even increase muscle mass. The European Heart Journal review also pointed to selective androgen receptor modulators as potential adjuncts with synergistic benefit. These are not yet standard of care, but they signal the direction the field is heading — and they underscore that even the researchers developing these medications recognize that muscle preservation needs to be a co-equal treatment goal, not a footnote.

The Obesity Pillars working group also emphasized the importance of aerobic activity alongside resistance training — not as a replacement, but as a complement. Aerobic conditioning supports mitochondrial health, cardiovascular resilience, and insulin sensitivity in ways that resistance training alone does not fully address. The combination of structured lifting and consistent cardio, paired with high protein intake, represents the most evidence-aligned lifestyle stack currently available to men on GLP-1 therapy.

What This Means For You

Semaglutide can be a powerful ally in the fight against obesity and metabolic disease — but it is not a complete strategy on its own. The research is clear that significant muscle loss is a predictable consequence of pharmacologic weight loss when left unaddressed, and the downstream effects on metabolic rate, physical function, and long-term health are serious enough to demand a proactive response. The good news is that the interventions work. Lifting weights, hitting your protein targets, and staying consistent with your activity are not just general wellness advice — they are clinically validated countermeasures to a specific and measurable problem. Use the medication as the accelerant it is. Build the foundation underneath it so that the weight you lose is actually fat, and the body you uncover is stronger than the one you started with.